Cited by 432CRISPR and Genetic EngineeringMitochondrial Function and PathologyVirus-based gene therapy research

Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs

Open access
Bacman, Sandra R, Williams, Siôn L, Pinto, Milena, Peralta, Susana, Moraes, Carlos T·2013·Nature Medicine

Abstract

Mitochondrial diseases are commonly caused by mutated mitochondrial DNA (mtDNA), which in most cases coexists with wild-type mtDNA, resulting in mtDNA heteroplasmy. We have engineered transcription activator-like effector nucleases (TALENs) to localize to mitochondria and cleave different classes of pathogenic mtDNA mutations. Mitochondria-targeted TALEN (mitoTALEN) expression led to permanent reductions in deletion or point-mutant mtDNA in patient-derived cells, raising the possibility that these mitochondrial nucleases can be therapeutic for some mitochondrial diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm.3261

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • TALEN can be re-engineered to target and cleave mutant mitochondrial DNA in patient-derived cells, whereas mitochondrial genome-targeting CRISPR-Cas9 remains to be explored.

    “And moreover, TALEN can be re-engineered to target and cleave mutant mitochondrial DNA in patient-derived cells, 21 whereas mitochondrial genometargeting CRISPR-Cas9 remains an area to be explored.”

    From CRISPR-Cas9: a new and promising player in gene therapy (2015) · cites this paper as [21]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [11]Corral-Debrinski M Nat Genet 2 324 329 1992 1303288
  2. [24]Bayona-Bafaluy MP Blits B Battersby BJ Shoubridge EA Moraes CT Proc Natl Acad Sci U S A 102 14392 14397 2005 16179392 PMC1242285
  3. [25]Moraes CT Ricci E Bonilla E DiMauro S Schon EA Am J Hum Genet 50 934 949 1992 1315123 PMC1682620

Cited by

Sorted by citations

Authors
Bacman, S. R., Williams, S. L., Pinto, M., Peralta, S., & Moraes, C. T.
Affiliations
University of Miami (US)
Corresponding author
Moraes, Carlos T
Venue
Nature Medicine
Published
2013-08-04
Volume
19
Issue
9
Pages
1111-1113
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2018217184
Cited by
432
References
28
Citations by year
2026: 21 · 2025: 30 · 2024: 25 · 2023: 47 · 2022: 32 · 2021: 36 · 2020: 36 · 2019: 37 · 2018: 40 · 2017: 22 · 2016: 37 · 2015: 34 · 2014: 31 · 2013: 4
FWCI
15.81
Type
journal article
Language
en
Open access
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute on Aging (R01AG036871)
  • National Eye Institute (R01EY010804)
  • National Institute of Neurological Disorders and Stroke (R01NS079965)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
mitochondrial DNA mutations, mitochondrial heteroplasmy, mitochondrial disease, TALEN, mitochondrial targeting, mitochondrial DNA deletions, point mutations, cell therapy, mitochondrial respiration
MeSH terms
Amino Acid Sequence, DNA, Mitochondrial, Humans, Mitochondria, Molecular Sequence Data, Mutation, Osteosarcoma, Deoxyribonucleases, Type II Site-Specific, Mitochondrial Diseases, Cell Line, Tumor, Genome, Mitochondrial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review